Cancer Discovery publishes high-impact, peer-reviewed articles describing major advances in research and clinical trials. As the premier cancer information resource, the Journal also presents Review Articles, Perspectives and Commentaries, News stories, and Research Watch summaries of important journal articles to its readers to keep them informed about the latest findings in the field. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic and epidemiologic studies
癌症发现发表高影响力，同行评审的文章，描述了研究和临床试验的主要进展。作为首要的癌症信息资源，该杂志还向读者提供评论文章、观点和评论、新闻报道和重要期刊文章的研究观察摘要，以使他们了解该领域的最新发现。主题涵盖癌症研究和医学的范围，从实验室到临床和流行病学研究
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1119
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1218
Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-0065
Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1453
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-0839
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1151
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.cd-18-0830
The Biology of m6A RNA Methylation in Normal and Malignant Hematopoiesis.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-0959
Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0582
Altered RNA Processing in Cancer Pathogenesis and Therapy.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0399
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-0348
Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0442
ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1308
Distinct CRC-associated APC mutations dictate response to Tankyrase inhibition.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0289
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-18-1138
Innate αβ T cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0161
Atezolizumab Combo Approved for PD-L1-positive TNBC.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-038
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-19-0487
Capivasertib Active against AKT1-Mutated Cancers.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2018-153
A Bispecific Antibody for MUC16 and CD3 Has Preclinical Antitumor Activity.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-099
GITR Agonism Overcomes Resistance to Immunotherapy in Solid Tumors.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-070
Brain Tumors Feed Off Healthy Neurons.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-117
Gilteritinib Likely New Standard Care for AML.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-046
Translesion Synthesis by DNA Polymerase θ Protects from Skin Cancers.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-025
R-Loops May Drive Embryonal Tumors with Multilayered Rosettes.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-186
Tumor Burden Affects Efficacy of Combination Immunotherapy.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-021
Enzalutamide Bests Older NSAAs in mHSPC.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-066
Fatty Acid Transport Regulates Neutrophil Function in Tumors.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-064
RAF Binding Preferences Dictate RAS-Mediated Tumorigenesis.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-158
NK Cells in the Tumor Microenvironment Have Fragmented Mitochondria.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-165
Oncogenic Gene Fusion-Derived Neoantigens Elicit Specific T-cell Responses.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-065
Structure-Based Design Identifies PROTAC Degraders of BAF Complex Subunits.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-094
Scientists See Human Cancer in Zebrafish.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-062
Bringing Oncohistones into the Fold.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.cd-19-0839
γ-Secretase Inhibitors Improve Multiple Myeloma BCMA CAR-T Therapy.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-153
3-D Imaging Reveals Why Tumors Grow In or Out.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-017
The PRIMPOL Protein Shields Replication Forks in BRCA-Deficient Cells.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-168
Mechanism of Cediranib/Olaparib Combo Revealed.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-064
NCI Paylines Drop as Grant Applications Climb.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-041
Rare Neuroepithelial Stem Cells May Underlie Small-Cell Lung Cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-154
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-077
AML Is Dependent on an RNA-Binding Protein Network.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-027
Pegilodecakin plus Anti-PD-1 Is Tolerable and Effective.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-152
Exact Sciences Buys Genomic Health for $2.8 Billion.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-099
New ADC Shrinks HER2-Positive Tumors.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-089
Lung Microbiota Promote Lung Cancer.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-019
Colon Cancer Data Key as Pfizer Buys Array.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-NB2019-075
The cGAS-STING Pathway Influences Taxane Response.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-111
YTHDF2 Is Required for Leukemia Stem Cells Function in AML.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-069
Tumor MHC-II Neoantigens Maintain CD8+ T-cell Antitumor Immunity.
来源期刊：Cancer discoveryDOI：10.1158/2159-8290.CD-RW2019-166
